Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Benzinga
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ENOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ENOV
Wall Street analysts forecast ENOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENOV is 45.25 USD with a low forecast of 40.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.980
Low
40.00
Averages
45.25
High
50.00
Current: 21.980
Low
40.00
Averages
45.25
High
50.00
About ENOV
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oversold Stocks: Travere, Hims, and Enovis Present Buying Opportunities
- Travere Drug Review Extended: The FDA has extended the review timeline for Travere Therapeutics' Filspari sNDA to April 13, causing the stock to drop approximately 23% over the past month, with an RSI of 29.7 indicating oversold conditions that may present a buying opportunity for investors.
- Hims Stock Coverage Initiated: Evercore ISI analyst initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33, despite the stock falling around 13% in the last month, with an RSI of 29.7 suggesting undervaluation that could attract investor interest.
- Enovis Buy Rating Issued: BTIG analyst assigned a Buy rating to Enovis Corp with a price target of $41, even as the stock declined about 14% in the past five days, with an RSI of 29.6 indicating oversold conditions that may offer potential rebound opportunities for investors.
- Market Trend Analysis: Benzinga Pro's charting tools indicate that trends in Hims and Enovis stocks are forming, allowing investors to leverage these oversold signals for strategic positioning and capitalize on potential market rebounds.
Continue Reading
Analysts Adjust Ratings on Wealthfront and Spire Global with Price Targets
- Wealthfront Rating Initiation: Keybanc analyst Alex Markgraff initiated coverage on Wealthfront Corp (NASDAQ:WLTH) with a Sector Weight rating, reflecting a cautious market sentiment as shares closed at $13.65.
- Spire Global Buy Rating: HC Wainwright & Co. analyst Scott Buck initiated coverage on Spire Global Inc (NYSE:SPIR) with a Buy rating and a price target of $14, indicating strong confidence in its growth potential as shares closed at $8.21.
- Enovis Rating Upgrade: BTIG analyst Ryan Zimmerman initiated coverage on Enovis Corp (NYSE:ENOV) with a Buy rating and a price target of $41, suggesting optimistic market expectations as shares closed at $27.01.
- Evommune Rating Initiation: HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Evommune Inc (NYSE:EVMN) with a Buy rating and a price target of $35, reflecting a positive outlook as shares closed at $15.37.
Continue Reading